Finally, we analyzed the impact of this miR-375/SEC23A axis on cell proliferation and viability especially in association with vandetanib, a clinically relevant cancer drug for treatment of metastatic MTC patients. The gene discussed is SEC23A; the disease is medullary thyroid gland carcinoma.